![]() Storage: After addition of gallium Ga 68 chloride to the reaction vial, use Ga 68 dotatate injection within 4 hours. Consult product information for detailed instructions regarding preparation of the radionuclide. Dispose of any unused drug in a safe manner in compliance with applicable regulations. ![]() Use waterproof gloves during the entire handling and administration process. To minimize radiation exposure, maintain adequate shielding during the life of the product. The solution is clear and colorless discard if the vial contains particulate matter or if the solution is discolored. Visually inspect parenteral products for particulate matter and discoloration. NOTE: Storage and disposal should be controlled in compliance with appropriate regulations of the governmental agency authorized to license the use of radiopharmaceuticals. Radiopharmaceuticals should only be used by nuclear physicians and/or radiopharmacists who are qualified by specific training and experienced in the safe use and handling of radioactive material, and whose experience and training have been approved by the appropriate governmental agency authorized to license the use of radiopharmaceuticals. To minimize radiation exposure to occupational workers and patients, observe appropriate precautions that are consistent with proper patient management. Before reconstitution and radiolabeling with gallium Ga 68, the contents of the kit are not radioactive. NOTE: The radionuclide is not part of the kit. Patients should drink and void frequently during the first hours after administration to reduce radiation exposure. ![]() NOTE: Instruct patients to drink a sufficient amount of water to ensure adequate hydration prior to the administration of gallium Ga 68 dotatate. Gallium Ga 68 dotatate was FDA-approved in June 2016.įor storage information, see the specific product information within the How Supplied section. The uptake of gallium Ga 68 dotatate may need to be confirmed by histopathology or other assessments. This uptake can also be seen in a variety of other tumor types or other pathologic conditions, or might occur as a normal variant. The uptake of gallium Ga 68 dotatate reflects the level of somatostatin receptor density in NETs. NETs have receptors for somatostatin, a hormone that regulates the endocrine system. NETs are rare benign or malignant tumors that develop in the hormone-producing cells of the body's neuroendocrine system, which are found in the stomach, intestines, pancreas, lungs, and other locations. All rights reserved.Gallium Ga 68 dotatate is a radioactive diagnostic agent for use with positron emission tomography (PET) for localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adults and pediatric patients. Even though NETs have historically been considered as rare tumors (orphan disease), their incidence has grown more than 500 percent over the last 3 decades. and the European Union is approximately 47,300 patients/year. The estimated incidence of NETs for the combined populations of the U.S. in two forms: as a kit for reconstitution using a Ga 68 generator, and as Netspot Injection, a ready-to-use dose delivered from a local radiopharmacy in selected metropolitan areas. The product will be available in the U.S. Gallium Ga 68 dotatate received Orphan Drug Designation from both the FDA and European Medicines Agency (EMA) in March 2014.įollowing approval, Netspot will be made available to the U.S. It is the first approved drug using Ga 68 as a positron emitter. Netspot is the new market name for Somakit-TATE (a kit for the preparation of gallium Ga 68 dotatate injection) in the U.S. Netspot received approval following a Priority Review from the FDA. The FDA has approved Netspot (Somakit-TATE) for the localization of somatostatin receptor positive neuroendocrine tumors (NETs) in adult and pediatric patients.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |